Each spray of Lenzetto delivers 1.53mg of estradiol as the active ingredient. The inactive ingredients include ethanol, octisalate (an organic UV-absorbing compound), and purified water. The presence of octisalate is why sunscreen should not be applied to the application site within one hour of use. If you have a known sensitivity to any of these components, discuss this with your clinician before starting treatment.

Lenzetto is available in three dose levels, all applied once daily:

• 1 spray (1.53mg estradiol) — very low dose; the standard starting point for most women
• 2 sprays (3.06mg estradiol) — low dose; used if one spray does not adequately control symptoms
• 3 sprays (4.59mg estradiol) — standard dose; the maximum daily dose

Your clinician will work with you to find the lowest effective dose for your symptoms. Dose adjustments are typically reviewed at your three-month appointment.

Many women notice early improvements in symptoms within two to four weeks of starting Lenzetto, with full benefits typically seen after around three months of consistent use. If you are seeing some improvement but symptoms are not well controlled, your clinician may adjust your dose at the three-month review. If there has been no improvement at all after three months, your clinician may check your oestrogen levels with a blood test, as absorption can vary between individuals.

There is no strong clinical evidence that Lenzetto causes weight gain. Some women notice temporary fluid retention, which is usually related to hormonal shifts during menopause itself rather than the treatment. Weight changes during the menopause transition are common and are driven by the underlying hormonal changes of menopause, not by transdermal oestrogen.

Whether bleeding is expected depends on the progestogen regimen you are using alongside Lenzetto. If you are on a sequential regimen, a regular withdrawal bleed is expected. If you are on a continuous combined regimen, bleeding should stop over time, though irregular spotting is common in the first few months. Vaginal spotting may also occur if progestogen is insufficient. If you are postmenopausal and experience unexpected bleeding at any point, contact your clinician it should always be assessed.

No, please do not adjust the number of sprays you use without speaking to your clinician first. While Lenzetto allows for flexible dosing between one and three sprays, the right dose for you depends on a clinical assessment of your symptoms and hormone levels. If you feel your current dose is not controlling your symptoms adequately, raise this at your review.

Lenzetto, Oestrogel, and Sandrena all deliver transdermal estradiol but in different formats. Lenzetto is a metered-dose spray applied to the forearm, each spray is a precise, pre-measured dose, removing the variability that can occur when measuring gel. Oestrogel is a pump-dispensed gel applied to a larger skin area, while Sandrena comes in pre-dosed sachets. Compared to patches such as Evorel or Estradot, Lenzetto avoids adhesive contact with the skin entirely, which suits women who experience patch-related skin reactions. A meta-analysis found the spray to be equivalent in efficacy to patches for vasomotor symptoms, with better local skin tolerability.